Region-specific glucocorticoid receptor promoter methylation has both positive and negative prognostic value in patients with estrogen receptor-positive breast cancer

Hilary Snider1,2, Brithica Villavarajan1, Yingwei Peng3,4,5, Lois E. Shepherd2,6, Andrew C. Robinson7 and Christopher R. Mueller1,2,8*

Abstract

Background: The glucocorticoid receptor (NR3C1, GR) is frequently downregulated in breast tumors, and evidence suggests it acts as a tumor suppressor in estrogen receptor-positive (ER+) breast cancer. We previously found that methylation of the GR promoter CpG island represses gene expression and occurs in ER+ breast tumors. In this study, the prognostic and predictive value of GR methylation was examined in ER+ patients from the CCTG MA.12 clinical trial of tamoxifen versus placebo in women with early breast cancer.

Methods: We developed a targeted multiplex bisulfite next-generation sequencing assay to detect methylation at multiple GR promoter regions in DNA from formalin-fixed paraffin-embedded (FFPE) samples. Following validation in a small cohort of breast tumors, ER+ FFPE tumor samples from MA.12 (n = 208) were tested. Survival analyses evaluated the impact of GR promoter methylation on patient overall survival (OS) and disease-free survival (DFS).

Results: An analysis of TCGA data found that GR methylation is prevalent in ER+ tumors and is associated with decreased gene expression and analysis of public microarray data (KM Plotter) linked decreased GR expression to a poor outcome. In MA.12, two GR promoter regions (U and C) each had prognostic value, but with opposite effects on the outcome. U methylation was associated with poor OS (HR = 1.79, P = 0.041) whereas C methylation was associated with better OS (HR = 0.40, P = 0.040) and DFS (HR = 0.49, P = 0.037). The classification of patients based on the methylation status of the two regions was prognostic for OS (P = 0.006) and DFS (P = 0.041) and revealed a group of patients (U methylated, C unmethylated) with very poor outcomes. Placebo-treated patients in this high-risk group had worse OS (HR = 2.86, P = 0.002) and DFS (HR = 2.09, P = 0.014) compared to the rest of the cohort.

Conclusion: Region-specific GR promoter methylation was an independent prognostic marker for patient survival and identified a subset of patients with poor prognosis, particularly without tamoxifen treatment. These findings provide a foundation for future studies into GR methylation as a promising prognostic biomarker in ER+ breast cancer.

Keywords: Breast cancer, Glucocorticoid receptor, DNA methylation, Prognosis, Bisulfite sequencing

* Correspondence: muellerc@queensu.ca
1Division of Cancer Biology and Genetics, Queen's Cancer Research Institute, Queen’s University, Kingston, Ontario, Canada
2Department of Pathology and Molecular Medicine, Queen’s University, Kingston, Ontario, Canada
Full list of author information is available at the end of the article

© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Breast cancer is a heterogeneous disease, so determining an accurate and specific prognosis is essential to ensure that each patient receives the most effective course of treatment. A prognosis is typically based on a combination of clinical characteristics (patient age, tumor size, tumor grade, and lymph node involvement) and histopathological features such as hormone receptor status [1, 2]. The majority of breast cancers express the estrogen receptor (ER) and are therefore responsive to endocrine therapies that impair estrogen signaling. Tamoxifen, a selective estrogen receptor modulator, has been the standard of care for ER+ patients for over 30 years. Its use has reduced recurrence rates by nearly one-half and has decreased disease mortality by about one-third [3–5]. Nevertheless, around 1 in 4 women treated with tamoxifen relapse within 10 years of treatment [3, 6]; thus, resistance to endocrine therapy is a major clinical concern and it is evident that ER status alone is insufficient to predict treatment response. Several multigene expression profiling assays have been developed as prognostic tools for the ER+ patient population including OncotypeDX, Prosigna (PAM50-based), and MammaPrint, all of which are in clinical use [2, 7, 8]. Although these tests further stratify ER+ patients by recurrence risk, their primary utility is to identify individuals who can safely be spared chemotherapy and they do not usually influence endocrine therapy treatment decisions [2, 7, 8]. Due to the limitations of current prognostic and predictive tools, there is an urgent need for the development of robust markers that can predict patient response to therapy prior to them undergoing treatment, allowing for timely interventions to minimize their risk of relapse and maximize survival.

The failure of endocrine therapies like tamoxifen can often be attributed to factors that modify or bypass the ER signaling pathway. De novo or pre-existing ER mutants account for a significant fraction of therapy failures, but the majority are due to other causes [9]. Recently, several studies have demonstrated that the expression and activation of the glucocorticoid receptor (GR) have a direct impact on the regulation of many ER target genes (reviewed in [10–12]). This is mediated by the crosstalk that occurs between GR and ER in their role as transcriptional regulators. The coactivation of both receptors leads to the recruitment of GR to ER DNA binding sites, which can have both cooperative and antagonistic gene-specific outcomes [13–16]. In ER+ breast cancer cells that express GR, the activation of both receptors, as opposed to ER alone, results in the increased expression of pro-differentiation genes which are associated with improved relapse-free survival in ER+ patients [13]. GR can also impede estrogen-stimulated cell growth by directly blocking the recruitment of transcriptional coactivators to ER-bound enhancers, repressing the transcription of estrogen-activated genes [17]. Overall, it appears that by modulating ER-directed gene transcription, GR promotes a more indolent tumor phenotype in ER+ breast cancers. The loss of this effect could permit cells to continue to survive and proliferate despite being subjected to ER-targeted therapies, leading to poor treatment response. Indeed, studies have found that low GR expression in ER+ breast cancer is associated with worse patient outcomes [13, 18].

Multiple studies have established that GR protein is frequently decreased in breast tumors in comparison to normal tissue [19–23], and lower GR expression is associated with higher tumor grade [20, 21]. We have previously identified that methylation of the GR gene (NR3C1) promoter is a common event that contributes to the downregulation of GR in breast cancer [24]. We found that while the GR promoter is not methylated in normal mammary tissue, it is methylated in approximately 15% of breast tumors. These GR-methylated tumors exhibited particularly low GR expression and were predominantly ER+. Given that methylation influences GR expression and that low GR-expressing tumors have been associated with poor relapse-free survival in ER+ tamoxifen-treated patients [13, 18], we propose that GR methylation may act as a biomarker for increased relapse risk and/or poor survival. In this study, we developed a multiplex bisulfite sequencing assay for detecting GR promoter methylation and used it to investigate the prognostic and predictive significance of GR methylation in a cohort of ER+ patients from a placebo-controlled trial of adjuvant tamoxifen in premenopausal women with early breast cancer (CCTG MA.12). This study is an excellent model for the analysis of methylation in archival clinical trial material.

Methods
MA.12 patient cohort
The Canadian Cancer Trials Group (CCTG) MA.12 study was a randomized placebo-controlled phase III trial of adjuvant tamoxifen for 5 years in premenopausal women with high-risk early breast cancer. The MA.12 trial was approved by local research ethics boards (Queen’s University DBMS-049-15) and participants provided a written informed consent. Between 1993 and 2000, 672 women were enrolled in MA.12. The median age was 46 years (range 29–58). After surgery, patients received standard adjuvant chemotherapy (cyclophosphamide/methotrexate/5-fluorouracil (CMF), cyclophosphamide/epirubicin/5-fluorouracil (CEF), or doxorubicin (adriamycin)/cyclophosphamide (AC)) followed by randomization to tamoxifen or placebo for 5 years. Levels of at least one hormone receptor (ER and/or PR) were determined by biochemical or immunohistochemical methods, but patients were eligible regardless of receptor status. The clinical endpoints were overall
survival (OS) and disease-free survival (DFS). OS was defined as the time from randomization to date of death or censored on the last date the patient was known to be alive, and DFS was defined as the time from randomization to the earliest date of recurrence or death or censored on the last date the patient was known to be alive. The median follow-up of the study was 9.7 years. The details on the conduct of this study and its results have been published [25].

Formalin-fixed, paraffin-embedded (FFPE) blocks were requested for all 454 ER+ patients from the study and a total of 252 tumor samples were available. Samples that did not pass the DNA extraction criteria (DNA concentration > 5 ng/μL) were excluded (n = 43), as was one sample with missing outcome data. This resulted in a final study cohort of 208 patients, the characteristics of which are summarized in Table 1.

### DNA extraction and bisulfite conversion

Archival FFPE blocks from the MA.12 clinical trial had three 1.0 mm tissue cores extracted for DNA isolation. Cores were deparaffinized with xylene and rinsed with 100% ethanol, and DNA was extracted with the AllPrep DNA/RNA FFPE Kit (Qiagen) as per manufacturer’s instructions. Quantitation of DNA yield was performed with a Qiaxpert spectrophotometer (Qiagen), and samples with a minimum DNA concentration of 5 ng/μL (140 ng total yield) were subjected to bisulfite conversion.

DNA was extracted from the MCF-7 and T47-D human breast cancer cell lines using the GenElute Mammalian Genomic DNA Mini-Prep Kit (Sigma-Aldrich) as described by the manufacturer. The isolation of DNA from MCF-7 and T47-D FFPE cell pellets was performed using the same methods as the MA.12 samples, outlined above. DNA from the Ontario Tumor Bank fresh frozen breast tumor samples used in this study was extracted previously, as described in [24]. Briefly, tumor samples were completely homogenized, and DNA extraction was carried out using the AllPrep DNA/RNA Mini Kit (Qiagen).

All DNA samples in this study were bisulfite converted using the EpiTect Fast DNA Bisulfite Kit (Qiagen) following the manufacturer’s protocol.

### Quantitative methylation-specific PCR

Quantitative methylation-specific PCR (qMSP) was conducted using primer sets (Additional file 1: Table S1, hg19 genomic coordinates in Additional file 2: Table S2) designed using MethPrimer [26] to specifically amplify either the methylated or unmethylated bisulfite-converted target sequence. For each reaction, 10 ng bisulfite-converted DNA was amplified using 1X QuantiTect SYBR Green PCR Master Mix (Qiagen) and 50 ng forward and reverse primers in a 20 μL volume. The assay was performed in an Applied Biosystems Viia 7 Real-Time PCR System (Life Technologies) with the following conditions: 95 °C for 15 min, followed by 40 cycles of denaturing at 95 °C for 30 s, annealing at 58 °C for 30 s, and elongation at 72 °C for 30 s. Cycle threshold (Ct) values were obtained for both the methylated-specific (M) and unmethylated-specific (U) primer sets and percent methylation was calculated for each sample using the following formula: % methylation = 100/(1 + 2^{ΔCt(M-U)}) %. PCR products were visualized by running 4 μL sample on 2.5% agarose gels.

### Library construction and bisulfite sequencing

Bisulfite sequencing libraries were created using a two-step PCR process. Primary PCR (singleplex or multiplex) was performed with GR bisulfite sequencing primers (Table 2) to amplify target GR promoter regions (Additional file 2: Table S2), followed by a secondary PCR for the addition of barcoded sequencing adapters.

### Table 1 Patient cohort characteristics

| Characteristic             | All ER+ MA.12 patients (N = 454) | GR methylation study cohort (N = 208) |
|----------------------------|----------------------------------|--------------------------------------|
|                            | N  | %    | N  | %    |
| **Age**                    |    |      |    |      |
| ≤ 45 years                 | 268 | 59.0 | 125 | 60.1 |
| > 45 years                 | 186 | 41.0 | 83  | 39.9 |
| **Stage (pathological)**   |    |      |    |      |
| I                          | 40  | 8.8  | 12  | 5.8  |
| II                         | 387 | 85.2 | 180 | 86.5 |
| III                        | 27  | 5.9  | 16  | 7.7  |
| **Tumor stage (T-stage)**  |    |      |    |      |
| T1                         | 212 | 46.7 | 90  | 43.3 |
| T2                         | 213 | 46.9 | 102 | 49.0 |
| T3/T4                      | 29  | 6.4  | 16  | 7.7  |
| **Nodal status**           |    |      |    |      |
| Node negative              | 87  | 19.2 | 28  | 13.5 |
| 1–3 nodes                  | 276 | 60.8 | 130 | 62.5 |
| 4–9 nodes                  | 78  | 17.2 | 42  | 20.2 |
| 10+ nodes                  | 13  | 2.9  | 8   | 3.8  |
| **Adjuvant chemotherapy**  |    |      |    |      |
| CEF                        | 104 | 22.9 | 52  | 25.0 |
| CMF                        | 197 | 43.4 | 89  | 42.8 |
| AC                         | 153 | 33.7 | 67  | 32.2 |
| **Treatment**              |    |      |    |      |
| Placebo                    | 231 | 50.9 | 112 | 53.8 |
| Tamoxifen                  | 223 | 49.1 | 96  | 46.2 |
| **Outcome**                |    |      |    |      |
| Deaths                     | 107 | 23.6 | 56  | 26.9 |
| Recurrences                | 154 | 33.9 | 86  | 41.3 |
Singleplex bisulfite sequencing

PCR was carried out for each DNA sample as nine separate amplification reactions, each containing a single set of GR bisulfite sequencing primers. Primary reactions contained 5–10 ng bisulfite-converted DNA, 0.5 units HotStarTaq Plus DNA polymerase (Qiagen), 1X PCR buffer (Qiagen), 0.2 mM dNTPs, and 0.2 μM forward and reverse primers in a 25 μL volume. PCR conditions were 95 °C for 10 min followed by 40 cycles of denaturing at 95 °C for 30 s, annealing at 55 °C for 45 s, elongation at 72 °C for 30 s, followed by a final extension at 72 °C for 7 min. Secondary PCR for sample barcoding was performed in 50 μL reactions using 2 μL primary PCR product, 0.5 U Qiagen Hot-StarTaq Plus (Qiagen), 1X PCR buffer (Qiagen), 0.2 mM dNTPs, 3 mM MgCl₂, and 0.08 μM of forward (barcoded) and reverse sequencing primers. PCR conditions were 95 °C for 15 min followed by 35 cycles of denaturing at 95 °C for 30 s, annealing at 60 °C for 90 s, and elongation at 72 °C for 90 s, followed by a final extension at 68 °C for 10 min. Products were purified with Agencourt AmpureXP magnetic beads (Beckman Coulter) and eluted in 20 μL of water. Secondary PCR for sample barcoding was performed in 50 μL reactions as described above for singleplex library preparation, using 10 μL purified primary multiplex PCR product as a template. Samples were quantified by Qubit dsDNA High Sensitivity fluorometric assay (Invitrogen), pooled at equal concentrations, and then purified with Agencourt AmpureXP magnetic beads (Beckman Coulter) followed by Ion Torrent sequencing.

Multiplex bisulfite sequencing

PCR was carried out for each DNA sample as a single reaction containing the nine GR bisulfite primer sets. Primary reactions contained 10 ng bisulfite converted DNA, 1X Multiplex PCR Plus Master Mix (Qiagen), and 0.8 μM multiplex primer mix (each primer), composed of GR bisulfite sequencing forward and reverse primers, in a 25-μL reaction volume. PCR conditions were 95 °C for 15 min followed by 35 cycles of denaturing at 95 °C for 30 s, annealing at 60 °C for 90 s, and elongation at 72 °C for 90 s, followed by a final extension at 68 °C for 10 min. Products were purified with Agencourt AmpureXP magnetic beads (Beckman Coulter) and eluted in 20 μL of water. Secondary PCR for sample barcoding was performed in 50 μL reactions as described above for singleplex library preparation, using 10 μL purified primary multiplex PCR product as a template. Samples were quantified by Qubit dsDNA High Sensitivity fluorometric assay (Invitrogen), pooled at equal concentrations, and then purified with Agencourt AmpureXP magnetic beads (Beckman Coulter) followed by Ion Torrent sequencing.

Bisulfite sequencing data processing

Sequencing-generated BAM files for each sample were uploaded to the Galaxy web platform [28] for processing prior to methylation analysis. The sequence files were
groups using Student GR mRNA expression levels were compared between invasive carcinoma [BRCA] dataset. Normalized relative status and 98 normal breast samples from the breast in-obtained for 363 breast tumor samples with positive ERome Atlas (TCGA) (https://cancergenome.nih.gov/) wasMethylation450K (HM50K) data from The Cancer Gen-publi. Care available level 3 RNAseq and Illumina Human-Statistical analysisregion and all but one patient had 3 or less.ever, most of these patients were missing data for only 1-ing value due to minimum coverage requirements; how-ever, most of these patients were missing data for only 1 region and all but one patient had 3 or less.

**Statistical analysis**

Publicly available level 3 RNAseq and Illumina Human-Methylation450K (HM50K) data from The Cancer Genome Atlas (TCGA) (https://cancergenome.nih.gov/) was obtained for 363 breast tumor samples with positive ER status and 98 normal breast samples from the breast invasive carcinoma [BRCA] dataset. Normalized relative GR mRNA expression levels were compared between groups using Student's t test. Differences in methylation between sample groups were assessed by Mann-Whitney U test. The relationship between relative gene expression values and mean methylation values for HM450K probes throughout the GR promoter (Additional file 2: Table S2) was assessed by Spearman rank correlation. All statistical analyses with TCGA data were conducted using GraphPad Prism 6.0.

To assess the relationship between methylation values from the singleplex and multiplex assays, two-tailed Pearson correlation coefficients were calculated with GraphPad Prism 6.0. All other analyses were performed using SPSS version 25.0 (IBM Corp, 2017). OS and DFS were described by Kaplan-Meier curves, with the difference between groups compared by log-rank test. Cox proportional hazards models were also used to assess the impact of prognostic factors on OS and DFS, as well as multivariate Cox models adjusting for age, tumor stage, nodal status, type of chemotherapy, and treatment. Multivariate Cox models with the same covariates, including an additional interaction term between treatment and GR methylation, were used to assess predictive value in OS and DFS. The chi-squared test, or Fisher’s exact test if at least one category was equal to 5 or less, was used to evaluate the relationship between GR methylation and clinical characteristics. All statistical tests were two-sided and P values of < 0.05 were considered significant.

For analysis of GR expression levels in breast cancer microarray studies, Kaplan-Meier plotter [30] was used to generate Kaplan-Meier curves for all ER+ patients regardless of treatment and for ER+ patients treated with tamoxifen. The overall survival and relapse-free survival of patients with high versus low GR expression were compared. The JetSet best probe set for the GR gene NR3CI, 216321_s_at, and an optimized threshold for the cutoff between high and low GR expression was used for all analyses. Hazard ratio (with 95% confidence interval) and log-rank P values were calculated by Kaplan-Meier plotter.

**Results**

**ER+ breast tumors exhibit reduced GR expression levels and increased promoter methylation compared to normal breast tissue**

The GR gene, NR3CI, has nine alternative first exons that are controlled independently by separate promoters [31, 32]. The first exon promoters that regulate GR expression in the breast are found within a 3-kb CpG island that spans the proximal promoter region of the gene and is susceptible to DNA methylation [24]. In a previous study, we showed that breast tumors had decreased GR expression compared to matched normal tissue and found that a subset of predominantly ER+ tumors exhibited methylation throughout the GR CpG island promoter region [24]. To further examine the role of GR methylation in ER+ breast cancer, we profiled GR expression and methylation in samples from the TCGA breast cohort. RNAseq and Illumina HumanMethylation450K (HM450K) data was obtained for 98 normal breast samples and 363 ER+ breast tumors. GR mRNA expression levels were significantly lower in ER+ tumors than in the normal breast tissue samples (P < 0.0001, Fig. 1a), consistent with previous findings. Methylation of the GR promoter was assessed for each sample based on the mean methylation (β values) of the HM450K probes (17 CpGs) within the GR CpG island. This analysis revealed significantly higher levels of GR promoter methylation in the ER+ tumors than in the normal breast tissue samples (P < 0.0001), which all exhibited low levels of methylation in this region (Fig. 1b). There were 52 ER+ tumors (14.3%) with GR methylation levels exceeding all normal samples, and this subset of GR-methylated ER+ tumors exhibited significantly reduced GR expression compared to the rest of the ER+ tumors (P < 0.0001, Fig. 1c). Next, the relationship between DNA methylation and gene expression in ER+ tumors was assessed at each HM450K probe within the GR gene. Results of the Spearman correlation showed that GR expression was significantly inversely correlated...
with methylation \((P < 0.05)\) at 19 of 23 proximal promoter CpG sites, and the remainder of probes in the promoter displayed a negative trend (Fig. 1d). These results indicate that the expression of GR is frequently downregulated in ER+ by the aberrant methylation of its proximal promoter CpG island and suggests that many sites within the promoter region could be important for mediating this effect.

**Design of a targeted, bisulfite sequencing-based assay to detect GR promoter methylation**

To analyze GR promoter methylation in the MA.12 cohort, we designed a bisulfite sequencing-based assay that would be appropriate for working with the limited amounts and poor quality of material from archival formalin-fixed paraffin-embedded (FFPE) tumor. FFPE samples often yield only a limited amount of DNA that can be extensively fragmented [33]. Moreover, DNA is prone to degradation during the bisulfite conversion process, leading to further fragmentation of the sample and a reduction in the amount of amplifiable template for PCR [34]. To mitigate this, primer sets were designed to target short stretches of DNA (< 200 bp), which are less likely to contain strand breaks and more likely to be amplified successfully. Due to the high GC content of the GR proximal promoter and the reduced sequence complexity following bisulfite conversion, designing primers that were sufficiently specific was a challenge. By using degenerate primers (i.e., both C and T are present at the C of the CpG) containing up to 3 CpGs that are capable of annealing to the target region regardless of methylation status, we expanded the promoter regions that were suitable for primer placement. The result was an assay consisting of nine bisulfite PCR primer sets (T, W, P, A, L, C, D, U, and F) that each interrogates the methylation status of 7 to 17 CpGs in the GR proximal promoter (Fig. 2). Multiplexed PCR with the nine primer sets is performed to amplify the bisulfite-converted sample DNA, which is then followed by the next-generation sequencing (NGS) to evaluate GR methylation within the targeted promoter regions.

**Establishment of the GR bisulfite sequencing assay as a functional test of GR methylation in breast cell line controls**

The GR bisulfite sequencing assay was initially tested using two ER+ breast cell lines, MCF-7 and T47-D,
which had their GR methylation status determined by MeDIP-qPCR in our earlier study [24]. To further validate these previous findings, we performed quantitative methylation-specific PCR (qMSP). In agreement with the MeDIP-qPCR results, MCF-7 cells did not show any GR promoter methylation, whereas T47-D cells were methylated at each of the assayed promoter regions (Fig. 3a,b). Therefore, MCF-7 and T47-D cells were used as the negative and positive controls for GR methylation, respectively.

The performance of the nine GR bisulfite sequencing primer sets was first evaluated individually (singleplex) in the two cell line controls, prior to multiplexing. MCF-7 cells were unmethylated throughout the GR promoter (methylation ≤ 0.01 for all regions), and T47-D cells were methylated, with each primer set reporting a methylation value of at least 0.25 (Fig. 3c). This was consistent with the qMSP data, indicating that the individual primer sets were detecting GR methylation effectively. Although the F primer set region did not meet the minimum sequencing coverage requirements in the T47-D sample, because it performed well in MCF-7 cells, it was still included for testing in the multiplex version of the assay.

Next, the GR bisulfite sequencing assay was tested with MCF-7 and T47-D cells using the nine primer sets in a multiplex reaction. DNA extracted from FFPE MCF-7 and T47-D cell pellets was also tested to investigate assay performance in FFPE samples. As anticipated, the pattern of GR methylation from the singleplex bisulfite sequencing was similarly reproduced in both the cell line and cell pellet FFPE samples tested by the multiplex assay (Fig. 4a). This was also seen at the level of individual CpG sites contained between each primer pair. For example, in many cases, all CpG sites in an assayed region were either methylated or unmethylated, as was seen for the C primer set region; however, there were several examples in T47-D cells, such as the A region, where the pattern of methylation was more varied (Fig. 4b). These methylation patterns were conserved in the multiplex results from cell lines and in the FFPE cell pellets. This suggested that despite the fragmentation that occurs with the fixation and embedding process, the GR bisulfite sequencing assay was robust and would be applicable to DNA from FFPE samples.

---

Fig. 2 GR gene (NR3C1) proximal promoter with primer locations for bisulfite sequencing, MSP, and MeDIP-qPCR. The gene consists of eight coding exons (2-9α/β) and nine untranslated alternative first exons which are located in the distal and proximal promoter regions. The distal promoter is located approximately 30 kb upstream of the coding exons, and unlike the proximal promoter, it has minimal activity in the breast. The GR proximal promoter spans a 3 kb region approximately 5 kb upstream from the translation start site in exon 2 and contains seven alternative first exons (blue boxes). Primers for bisulfite sequencing (green bars depict the regions amplified by each primer set) were designed spanning the proximal promoter region and were used for our singleplex and multiplex GR bisulfite sequencing assay. MSP primer set regions are shown in purple and the location of qPCR primer sets for MeDIP-qPCR, performed in our previous study [24], are shown in orange. Genomic coordinates (hg19) for these regions are reported in Additional file 2: Table S2.
Multiplex GR bisulfite sequencing assay limit of detection
Tumor samples typically contain a mixture of cancerous and normal cells. Therefore, a dilution experiment was done to determine the ability of the multiplex bisulfite sequencing assay to detect GR-methylated tumor DNA against a background of DNA from GR-unmethylated cells. Varying amounts of T47-D DNA (10 to 0.01 ng) were added to a fixed 10 ng of DNA from MCF-7 cells to represent samples with a range of methylated tumor cells. A sample containing only MCF-7 DNA was assayed multiple times and used to set a methylation threshold for the primer sets in the assay (methylation ≥ 0.015), defined as three standard deviations above the mean methylation of all regions. With this cutoff, all primer sets in the multiplex assay detected 1 ng of methylated T47-D DNA in a background of 10 ng unmethylated DNA, and the C, D, and U primer sets could detect as little as 0.1 ng (Fig. 5). Thus, samples with from 10% to as little as 1% methylated tumor cells would still be classified as methylated by the GR bisulfite sequencing assay.

Validation of GR bisulfite sequencing assay in breast tumor samples
Tumors are composed of a heterogeneous population of cells, including stromal and immune cells, and as a result, they are more complex than cell lines. Therefore, prior to testing the MA.12 cohort, the GR bisulfite sequencing assay was validated with DNA extracted from breast tumor samples. A small cohort of fresh frozen breast tumors from the Ontario Tumour Bank had been tested with MeDIP-qPCR as part of our previous study to determine their GR methylation status [24]. Here, we examined a subset of these tumors that included both GR-methylated and GR-unmethylated samples. As with the MCF-7 and T47-D cell line controls, the GR methylation status of the tumors was confirmed by qMSP (Fig. 6a).

To ensure that the results from the singleplex and multiplex bisulfite sequencing assay remained consistent in this more complex sample type, several of the breast tumors were tested with both assay preparation methods and a Pearson correlation was used to assess the association between the results from each method. As anticipated, there was a strong positive correlation between the methylation values generated by both tests, for all the primer set regions. The correlations were statistically significant with all greater or equal to $r = 0.97$, $P < 0.0001$, with $R^2 = 0.942$ (Additional file 6: Figure S1).

Next, the multiplex assay was used to assess GR methylation in eight GR-methylated and eight GR-
Fig. 4 Singleplex and multiplex GR bisulfite sequencing in MCF-7 and T47-D cell lines and FFPE cell pellets. GR bisulfite sequencing was performed as a singleplex assay (separate reactions for each primer set) or a multiplex assay (all primer sets used in a single reaction) for cell lines and as a multiplex assay with DNA extracted from formalin-fixed paraffin-embedded cell pellets (Multiplex FFPE). a Heat map of mean methylation levels for each bisulfite sequencing region in the GR promoter. b Heat map of mean methylation level for each CpG contained within GR bisulfite sequencing region A (17 CpGs) and region C (10 CpGs) in T47-D cells.

---

Fig. 5 Multiplex GR bisulfite sequencing assay detection limit. T47-D (GR-methylated) DNA was added in varying amounts (10 to 0.01 ng) to a fixed amount (10 ng) of MCF-7 (GR-unmethylated) DNA. These mixtures (50%, 10%, 1%, and 0.1% T47-D DNA) and samples containing T47-D only (100%) and no T47-D DNA (0%, MCF-7 DNA only) were used to test the ability of the multiplex bisulfite sequencing assay to detect GR-methylated DNA in a background of unmethylated DNA. DNA from MCF-7 cells was assayed multiple times and was used to set a threshold for methylation which was defined as three standard deviations above the mean methylation level of all GR bisulfite sequencing regions (0.015, indicated by a dotted line). The primer sets for regions C, D, and U could detect as little as 1% T47-D DNA with this cutoff, and all could detect the sample with 10%.
unmethylated tumors (Fig. 6b). Overall, the results were in accordance with those from qMSP. GR-unmethylated tumor samples, similar to MCF-7 cells, lacked methylation at all of the interrogated primer regions (methylation ≤ 0.015 for all regions). In contrast, the GR-methylated tumors all had two or more promoter regions with methylation ≥ 0.05. In comparison to the methylation pattern observed in T47-D cells, methylation in the breast tumors was more spatially varied across the GR promoter, with several samples only exhibiting methylation at a subset of the interrogated promoter regions (Fig. 6b). However, this was not unexpected as it was reflective of the previous MeDIP-qPCR findings and was also apparent in the qMSP results. A single sample, D02130T, despite previously being identified as methylated by MeDIP-qPCR was not classified as methylated by the qMSP assay, yet results from singleplex and multiplex bisulfite sequencing both detected low levels of methylation at primer regions A and F. Further investigation at the CpG level revealed that methylation in this sample was localized to several small areas that did not coincide with the limited number of CpGs assessed by our qMSP probes. Altogether, analysis of the fresh frozen breast tumor samples further supports the integrity of the GR bisulfite sequencing assay and demonstrates its performance in a more complex sample type.

GR methylation as a prognostic marker in ER+ breast cancer patients from the MA.12 clinical trial cohort

The CCTG MA.12 study recruited 672 breast cancer patients, with 338 randomized to tamoxifen and 334 to placebo. There were 454 MA.12 patients with ER+ breast cancer, and 252 ER+ FFPE tumor samples were available for DNA extraction, 208 of which yielded enough material for bisulfite conversion and subsequent methylation assessment by multiplex bisulfite sequencing. The characteristics of all ER+ patients from the MA.12 trial (n = 454) and the patients in the GR methylation study cohort (n = 208) are described in Table 1. The clinicopathological characteristics were similar between the two cohorts. There were 56 deaths (26.9%) and 86 relapse events (41.3%) that occurred within the 208-patient GR methylation study cohort during the 9.7-year median follow-up time of the MA.12 trial. To investigate the clinical significance of GR promoter methylation in these patients, eight GR promoter regions were assessed by multiplex bisulfite sequencing (the T promoter region was excluded from analysis due to low sequencing coverage), methylation at each region was dichotomized according to the previously determined MCF-7-derived threshold, and the results were compared with patient overall survival (OS) and disease-free survival (DFS).
Univariate survival analyses performed for each of the eight GR promoter regions indicated that region C and region U were both potential prognostic factors for patient outcome in the whole methylation study cohort (Table 3, Fig. 7). Patients with methylation of region U had significantly worse OS (HR = 1.742, 95% CI 1.008–3.011; \( P = 0.047 \), Fig. 7a) compared to those without methylation in the U region. U region-methylated patients also had a poorer 5-year DFS rate (63.0% of patients relapse-free at 5 years versus 75.0% for unmethylated patients), although

| Characteristic          | OS Hazard ratio [95% CI] | P     | DFS Hazard ratio [95% CI] | P     |
|-------------------------|--------------------------|-------|---------------------------|-------|
| **Univariate analysis** |                          |       |                           |       |
| GR methylation          |                          |       |                           |       |
| A                       | 0.869 [0.445–1.698]      | 0.682 | 0.807 [0.464–1.403]       | 0.448 |
| C                       | 0.423 [0.181–0.986]      | 0.046 | 0.492 [0.261–0.927]       | 0.028 |
| D                       | 0.867 [0.437–1.722]      | 0.684 | 1.155 [0.692–1.928]       | 0.580 |
| F                       | 0.816 [0.457–1.457]      | 0.491 | 0.707 [0.438–1.140]       | 0.154 |
| L                       | 1.403 [0.750–2.625]      | 0.289 | 1.470 [0.886–2.438]       | 0.136 |
| P                       | 1.059 [0.518–2.164]      | 0.875 | 1.249 [0.725–2.155]       | 0.423 |
| U                       | 1.742 [1.008–3.011]      | 0.047 | 1.282 [0.803–2.046]       | 0.289 |
| W                       | 1.294 [0.716–2.339]      | 0.393 | 1.227 [0.755–1.997]       | 0.409 |
| Age                     |                          |       |                           |       |
| ≤ 45 years              | 1                        |       |                           |       |
| > 45 years              | 1.577 [0.933–2.666]      | 1.340 | 0.875–20.53               |       |
| Stage (pathological)    |                          | 0.8   |                           | 0.534 |
| I                       | 1                        |       |                           |       |
| II                      | 1.536 [0.380–6.428]      | 0.536 | 1.724 [0.543–5.470]       | 0.355 |
| III                     | 1.352 [0.247–7.381]      | 0.728 | 2.136 [0.566–8.055]       | 0.262 |
| Pathological T-stage    |                          | 0.094 |                           | 0.261 |
| T1                      | 1                        |       |                           |       |
| T2                      | 1.891 [1.059–3.377]      | 0.031 | 1.418 [0.903–2.228]       | 0.130 |
| T3/T4                   | 1.310 [0.440–3.898]      | 0.627 | 1.552 [0.713–3.379]       | 0.268 |
| Nodal status            |                          | 0.008 |                           | 0.007 |
| Node negative           | 1                        |       |                           |       |
| 1–3 nodes               | 1.071 [0.446–2.571]      | 0.878 | 1.679 [0.763–3.696]       | 0.198 |
| 4–9 nodes               | 1.357 [0.515–3.572]      | 0.537 | 1.832 [0.769–4.362]       | 0.172 |
| 10+ nodes               | 4.863 [1.565–15.109]     | 0.006 | 6.285 [2.106–18.754]      | 0.001 |
| Adjuvant chemotherapy   |                          | 0.31  |                           | 0.366 |
| CEF                     | 1                        |       |                           |       |
| CMF                     | 0.840 [0.446–1.583]      | 0.59  | 0.794 [0.473–1.332]       | 0.382 |
| AC                      | 0.570 [0.274–1.186]      | 0.133 | 0.662 [0.373–1.174]       | 0.158 |
| Treatment               |                          | 0.914 |                           | 0.489 |
| Placebo                 | 1                        |       |                           |       |
| Tamoxifen               | 1.029 [0.609–1.741]      | 0.860 | 0.561–1.318               |       |
| **Multivariate analysis**|                          |       |                           |       |
| GR methylation          |                          |       |                           |       |
| C                       | 0.396 [0.164–0.957]      | 0.04  | 0.492 [0.252–0.957]       | 0.037 |
| U                       | 1.786 [1.025–3.113]      | 0.041 | 1.318 [0.822–2.115]       | 0.252 |

Multivariate Cox proportional hazards models are adjusted for age, pathological stage, pathological T-stage, nodal status, type of adjuvant chemotherapy, and treatment arm. \( P \) values < 0.05 are shown in italics.
the methylation status of this region did not significantly impact DFS overall (HR = 1.282, 95% CI 0.803–2.046; \(P = 0.289\), Fig. 7b). Methylation of the C region was also associated with significant differences in patient outcome; however, unexpectedly, methylation in this region was associated with better OS (HR = 0.423, 95% CI 0.181–0.986; \(P = 0.046\), Fig. 7c) and DFS (HR = 0.492, 95% CI 0.261–0.927; \(P = 0.028\), Fig. 7d). Of the 86 relapse patients in the study cohort, 25 (29%) had tumors with U region methylation and 11 (13%) had C region methylation, including one patient with both U and C methylation (Additional file 3: Table S3). In the subset of patients who died (\(n = 56\)), U region methylation accounted for an even greater proportion of patients (20 patients, 36%) while instances of C region methylation remained relatively low (6 patients, 11%). Multivariate analysis, carried out for U and C region methylation separately, confirmed that these regions remained prognostic indicators of outcome independent of patient age, pathological stage, T-stage, nodal status, adjuvant chemotherapy, and treatment (placebo versus tamoxifen) (Table 3). Methylation of the remaining GR promoter regions was not associated with statistically significant differences in either OS or DFS (Table 3).

To further characterize the clinical significance of GR methylation in breast cancer, we examined the relationships between the methylation status of each promoter region and clinicopathological characteristics which are already known survival predictors including age, pathological stage, T-stage, and nodal status (Additional file 4: Table S4). Methylation of the C region and lower nodal involvement almost reached significance (\(P = 0.064\)), while L region methylation was associated with both higher pathological stage (\(P = 0.013\)) and higher nodal status (\(P = 0.023\)). Univariate survival analysis of clinicopathological characteristics demonstrated that the nodal status was a strong predictor of OS and DFS in our cohort and that higher T-stage (T2 vs T1) was associated with worse OS (Table 3).

The identification of two regions of the same promoter with opposite associations with OS and DFS is unusual. Given our expectation that GR methylation would in general be associated with worse outcome, one of the
simplest explanations is that the region C methylation is actually related to a lack of methylation over the rest of the promoter. Logistic regression analysis of the methylation status of these regions indicated that methylation of region C was inversely correlated with methylation in regions W, A, L, and U \((P < 0.05)\) supporting the idea that the better outcomes are due to decreased methylation across the rest of the promoter. There were 42 patients with methylation of region C and 54 with methylation of region U, but only 9 patients with both C and U region methylation indicating the two regions were mostly mutually exclusive. Of the 9 patients positive for both C and U, 5 were not methylated in regions W, A, or L suggesting the patients with C and U methylation were more similar to region C methylated tumors. Therefore, patients were divided into three groups according to the methylation status of the C and U regions: C methylated \((n = 42)\), U methylated without C methylation \((n = 45)\), and no methylation in either region \((n = 119)\). Univariate Cox proportional hazards models showed that both OS \((P = 0.006)\) and DFS \((P = 0.035)\) were statistically significantly different across these GR methylation groups (Table 4), with the C region methylation group having the best outcomes and the U region without C methylation group having the worst (Fig. 8a, b). There was no significant association between these GR methylation groups and patient clinicopathological characteristics (Additional file 5: Table S5).

In multivariate analysis adjusting for age, pathological stage, T-stage, nodal status, adjuvant chemotherapy, and treatment, GR methylation group remained an independent prognostic factor for OS and DFS (Table 4), with the same relationship between groups as observed in the univariate analysis. Patients with U methylation, but no C methylation had markedly worse OS compared to patients with no C or U region methylation \((HR = 1.988, 95\% CI 1.112–3.553; P = 0.02)\) and compared to patients in the C methylated group \((HR = 3.941, 95\% CI 1.540–10.085; P = 0.004)\). U methylation group patients also had an increased risk of relapsing compared to patients with C methylation \((HR = 2.560, 95\% CI 1.226–5.343; P = 0.012)\). Although it did not reach statistical significance, there was a trend towards better OS \((HR = 0.504, 95\% CI 0.203–1.255; P = 0.141)\) and DFS \((HR = 0.559, 95\% CI 0.280–1.115; P = 0.099)\) in the patients with C methylation compared to those with unmethylated C and U regions. Altogether these results suggest that methylation of the C and U bisulfite sequencing assay regions within the GR CpG island promoter have significant prognostic value in this cohort of ER+ breast cancer patients.

Since the MA.12 trial was used to validate PAM50 [35], we used the data available from that analysis to examine if our GR methylation groups based on C and U region methylation were related to any of the intrinsic PAM50 subtypes. Luminal B breast cancers for example have a poor prognosis compared to luminal A tumors and also have been associated with a particular methylation signature (CpG Island Methylator Phenotype, CIMP) [36, 37]. PAM50 data was available for 165 tumors in our study cohort. As expected, most were luminal A (46.7%) and luminal B (28.5%), with some HER-2 enriched (18.2%) and several basal (3.0%) and normal (3.6%) samples. There was no statistically significant difference in the distribution of PAM50 subtypes between our three GR methylation groups \((P = 0.327)\). Similarly, the risk of recurrence (ROR) scores, which are generated from PAM50 subtype data alone (RORS) or together with proliferation signature index (RORP) or tumor size (RORT), was also not significantly different between GR methylation groups (Table 5), suggesting that GR methylation is not associated with the PAM50 signature.

**GR methylation as a predictive marker of tamoxifen benefit in ER+ breast cancer patients from the MA.12 clinical trial cohort**

Even though the complete MA.12 trial was marginally positive for the effect of tamoxifen on DFS \((HR = 0.77, P = 0.06)\) and not significant for its effect on OS \((HR = 0.78, P = 0.12)\), we analyzed the relationship between the C and U region methylation groups and the effect of tamoxifen treatment (Fig. 9a, b, Table 6). Within the patients with U but not C methylation, there appeared to be a greater trend for benefit from tamoxifen, both in terms of OS \((P = 0.427)\) or DFS \((P = 0.723)\). Despite this, dividing patients according to both GR methylation group and treatment arm may have prognostic utility. While the U methylated, C unmethylated group of patients had worse outcomes overall, those also in the placebo arm had particularly poor OS \((adjusted HR = 2.855, 95\% CI 1.462–5.575; P = 0.002, Fig. 9c)\) and DFS \((adjusted HR = 2.091, 95\% CI 1.159–3.771; P = 0.014, Fig. 9d)\), when compared to the rest of the cohort as a whole. However, the small numbers of patients involved means these results should be treated with caution.

**Decreased GR expression in ER+ breast cancer correlates with poor clinical outcome in an independent cohort**

We expanded our investigation of GR as a marker of poor outcome in an independent cohort using the online survival analysis tool, Kaplan-Meier plotter [30]. The
multi-study breast cancer cohort assembled by Kaplan-Meier plotter contains gene expression data with extended patient survival information. The relationship between GR mRNA expression level (according to an optimized cutoff) and outcome was assessed for all ER+ patients, regardless of treatment regimen (Fig. 10a, b). Patients with low GR-expressing tumors exhibited an increased risk of breast cancer-related death \( (P = 0.0016) \) compared to those with high GR expression levels. A similar trend was observed with respect to the risk of relapse; however, it did not quite reach statistical significance \( (P = 0.067) \). Decreased GR expression levels also appeared to be detrimental in ER+ patients treated with tamoxifen (Fig. 10c, d), as it was marginally associated with poor OS \( (P = 0.068) \) and significantly associated with increased relapse risk \( (P = 0.0013) \). Given that decreased GR expression is an expected consequence of GR promoter methylation, these findings further support

| Table 4 | Cox proportional hazards analysis of disease-free survival and overall survival for GR methylation groups based on C and U region methylation status |
|-----------------|-----------------|-----------------|
| Characteristic | OS | DFS |
| Hazard ratio [95% CI] | Hazard ratio [95% CI] |
| P | P |
| | | |
| **Univariate analysis** | | |
| GR methylation group | | |
| Both C and U unmethylated | 1 | 1 |
| C methylated | 0.524 [0.218–1.260] | 0.149 | 0.549 [0.286–1.054] | 0.072 |
| U methylated, no C methylation | 2.008 [1.140–3.537] | 0.016 | 1.407 [0.864–2.291] | 0.170 |
| **Multivariate analysis** | | |
| Age | | |
| 45 years | 0.083 | 0.152 |
| > 45 years | 1.624 [0.939–2.810] | 1.389 [0.886–2.178] |
| Stage (pathological) | | |
| I | 0.985 | 0.976 |
| II | 1.054 [0.167–6.672] | 0.955 | 0.901 [0.179–4.529] | 0.899 |
| III | 0.731 [0.005–107.941] | 0.902 | 0.653 [0.015–27.996] | 0.824 |
| Pathological T-stage | | |
| T1 | 0.542 | 0.558 |
| T2 | 1.448 [0.751–2.790] | 0.269 | 1.313 [0.788–2.189] | 0.296 |
| T3/T4 | 1.401 [0.015–129.717] | 0.884 | 1.830 [0.073–46.030] | 0.713 |
| Nodal status | | |
| Node negative | 0.022 | 0.029 |
| 1–3 nodes | 1.052 [0.334–3.308] | 0.932 | 1.638 [0.540–4.972] | 0.383 |
| 4–9 nodes | 1.153 [0.337–3.945] | 0.82 | 1.569 [0.488–5.048] | 0.45 |
| 10+ nodes | 5.007 [1.201–20.875] | 0.027 | 6.004 [1.494–24.129] | 0.012 |
| Adjuvant chemotherapy | | |
| CEF | 0.517 | 0.624 |
| CMF | 1.018 [0.493–2.103] | 0.961 | 0.944 [0.519–1.718] | 0.851 |
| AC | 0.698 [0.319–1.526] | 0.367 | 0.755 [0.399–1.426] | 0.386 |
| Placebo | 0.552 | 0.136 |
| Tamoxifen | 0.844 [0.484–1.474] | 0.710 [0.452–1.115] | 0.012 |
| GR methylation group | | |
| Both C and U unmethylated | 0.006 | 0.041 |
| C methylated | 0.504 [0.203–1.255] | 0.141 | 0.559 [0.280–1.115] | 0.099 |
| U methylated, no C methylation | 1.988 [1.112–3.553] | 0.02 | 1.431 [0.866–2.365] | 0.162 |

Multivariate Cox proportional hazards models are adjusted for age, pathological stage, pathological T-stage, nodal status, type of adjuvant chemotherapy, and treatment arm, as shown. P values < 0.05 are shown in italics.
a role for GR methylation as a marker of poor outcome in ER+ breast cancer patients.

Discussion
As part of this study, we have developed a multiplexed next-generation sequencing protocol for the analysis of DNA methylation that optimizes the small quantities of nucleic acid material available from FFPE tissue for molecular-level analysis while limiting the cost of this type of analysis. This technique was effective for the assessment of DNA from fresh frozen tumor samples as well as material from the MA.12 clinical trial where the FFPE samples were from 18 to 25 years old. The ability to interrogate completed clinical trials is a singular advantage for characterizing the predictive power of specific biomarkers both within the context of the specific agents being tested but also in general. Access to archival samples in the form of FFPE tumor material allows

| Table 5 | Comparison of GR methylation groups with PAM50 characteristics |
|-----------------------|---------------------------------------------------------------|
| Characteristic       | C methylated | Both C and U unmethylated | U methylated, no C methylation | \( \chi^2 \) | \( P \) |
|-----------------------|--------------|---------------------------|---------------------------------|-------------|-------|
| PAM50 subtype         |              |                           |                                 |             |       |
| Luminal A             | 16           | 44.4                      | 48                              | 51.6        |       |
| Luminal B             | 14           | 38.9                      | 22                              | 23.7        |       |
| HER2                  | 5            | 13.9                      | 15                              | 16.1        |       |
| Basal                 | 1            | 2.8                       | 4                               | 4.3         |       |
| Normal                | 0            | 0.0                       | 4                               | 4.3         |       |
| RORS group            |              |                           |                                 |             |       |
| Low                   | 12           | 33.3                      | 38                              | 40.9        | 2.667 | 0.615 |
| Medium                | 18           | 50.0                      | 41                              | 44.1        |       |
| High                  | 6            | 16.7                      | 14                              | 15.1        |       |
| RORP group            |              |                           |                                 |             |       |
| Low                   | 10           | 27.8                      | 26                              | 28.0        | 3.475 | 0.482 |
| Medium                | 17           | 47.2                      | 52                              | 55.9        |       |
| High                  | 9            | 25.0                      | 15                              | 16.1        |       |
| RORT group            |              |                           |                                 |             |       |
| Low                   | 8            | 22.2                      | 26                              | 28.0        | 1.581 | 0.812 |
| Medium                | 19           | 52.8                      | 48                              | 51.6        |       |
| High                  | 9            | 25.0                      | 19                              | 20.4        |       |

PAM50 data was available for 165 samples
for the interrogation of protein, DNA, and RNA from these trials which often have many years of follow-up, which is in contrast to new comprehensive analyses such as TCGA in which follow-up is extremely limited [38]. Indeed, MA.12 was used to validate the PAM50 assay [35], which has come into clinical practice as the Prosigna test [39]. The value of DNA methylation biomarkers is increasingly recognized [40] and has distinct technical advantages in the context of FFPE material. Methylation markers are often highly tumor-specific and effect multiple CpGs, and as such do not suffer as extremely from the cellularity issues that limit both RNA quantification and DNA mutation analyses. Here, for example, we have demonstrated that levels of tumor DNA as low as 1% can be easily distinguished from normal DNA. Our approach also provides access to methylation analysis at the nucleotide level, interrogating more CpGs (7 to 17) than qMSP (generally 2–3). This has advantages when methylation is

Table 6 Predictive analysis of GR methylation groups

| GR methylation group | Treatment | # of patients | OS 5-year OS | Hazard ratio [95% CI] | P | P value for interaction | DFS 5-year DFS | Hazard ratio [95% CI] | P | P value for interaction |
|----------------------|-----------|---------------|---------------|------------------------|---|-------------------------|----------------|------------------------|---|------------------------|
| C methylated         | Placebo   | 27            | 92.6%         | 0.744 [0.058–9.598]     | 0.82 | 0.427                  | 81.5%         | 1.221 [0.266–5.597] | 0.789 | 0.723                  |
|                      | Tamoxifen | 15            | 93.3%         | 1                      |     |                        | 86.7%         | 1.221 [0.266–5.597] | 0.789 | 0.723                  |
| Both C and U unmethylated | Placebo   | 62            | 90.3%         | 1                      | 0.596 | 0.328                  | 72.6%         | 0.755 [0.418–1.361] | 0.328 | 0.328                  |
|                      | Tamoxifen | 57            | 87.5%         | 1.258 [0.563–2.493]    |     |                        | 73.2%         | 0.755 [0.418–1.361] | 0.328 | 0.328                  |
| U methylated, no C methylation | Placebo   | 23            | 65.2%         | 1                      | 0.105 | 0.081                  | 47.8%         | 0.430 [0.166–1.110] | 0.081 | 0.081                  |
|                      | Tamoxifen | 22            | 86.4%         | 0.414 [0.142–1.203]    |     |                        | 68.2%         | 0.430 [0.166–1.110] | 0.081 | 0.081                  |

Hazard ratios are adjusted for age, pathological stage, pathological T-stage, nodal status, and type of adjuvant chemotherapy.
spatially complex, as seen with sample D02130T, which was negative by qMSP but had localized methylation that was revealed by sequencing. For this study, we have analyzed 9 different sites across the highly complex glucocorticoid receptor proximal promoter, but this technique could just as easily be applied to 9 or more different regions across the genome.

DNA methylation markers in breast cancer are recognized as having the potential to aid in the management of patients by providing significant prognostic information [41]. Our observation of both positive and negative associations between methylation at the same gene is unusual in that most markers tend to be one or the other [41]. The relatively mutually exclusive nature of C region and methylation of other regions and particularly the U region may explain this inverse association. Furthermore, methylation at these two regions appears to have a differential effect on GR expression, as preliminary immunohistochemical staining of MA.12 tissue microarrays has revealed that GR staining (H-scores) in U methylated tumors is around 3-fold lower than tumors with C methylation (data not shown). Previous studies of GR expression and function in breast cancer have revealed a similarly complex situation involving both increased and decreased risk. In Triple-Negative Breast Cancer (TNBC), higher levels of GR expression have been associated with poor outcome [18]. This is thought to stem from the protective effect of activation of the stress response wherein the upregulation of SGK-1 by GR may lead to resistance to apoptosis [42]. More recently, GR activation has been observed in breast cancer metastases and was associated with a GR activation signature which included genes such as MELK, CDK1, and particularly the ROR1 family.

Fig. 10 Kaplan-Meier curves of overall survival (a, c) and disease-free survival in ER+ breast cancer patients from the KM plotter cohort divided by GR mRNA expression level. ER+ patients regardless of treatment received (a, b) or treated with tamoxifen (c, d) were grouped by high or low GR expression using an optimized cutoff. The JetSet probe for GR (NR3C1, 216321_s_at) was used for all analyses. Hazard ratios and log-rank P values were calculated by KM plotter. The number of patients (n) in each analysis is indicated.
methylation, which we have demonstrated to be very robust could serve as an ancillary marker and being based on DNA spared aggressive treatment [49]. The C region biomarker patients into risk groups where those with the lowest risk are commercial test, Prosigna, is typically is used to stratify pa-
tients with a basal phenotype. Of these, only 1 displayed C region methylation, and none had U region methylation; thus, our markers are unlikely to be associated with a TNBC phenotype.

In contrast with TNBC, in ER+ breast cancer, higher levels of GR mRNA are associated with good outcome [13, 18]. This may be associated with the induction of differentiation mediated through increased co-occupancy by ER and GR at multiple sites in the genome [13]. Similarly, the potential for GR to participate in the suppression of ER+ breast cancer proliferative gene expression by occupying ER-bound enhancers has also been recently described [45]. We have previ-
ously defined a tumor suppressor-like activity of the unliganded GR which activates multiple targets that may also result in the induction of differentiation, apoptosis, and growth arrest [46]. The transcriptional activation of BRCA1 expression in particular may be a target for this unliganded GR function [47]. Loss of GR expression through promoter methylation, and thus, of these tumor-suppressive GR functions, could contribute to breast cancer development and progression by allowing for increased cell survival and potentially increased tumor growth from a loss of GR-mediated regulation of ER signaling. We have also suggested that GR methylation could be linked to psychological stress [24] providing a link between stress and the etiology of breast cancer [48].

U region methylation was found in over 25% of patients, while C region methylation was found in 20% of patients, and with the two being mostly mutually exclusive, they provide an assessment in almost half of our patient cohort. MA.12 is also a relatively young cohort with a median age of 46 years (range 29–58) representing a pre- and peri-menopausal population where tamoxifen would be expected to be more effective [3]. Neither U or C methylation was associated with the PAM50 assessment of intrinsic phenotype indicating that their prognostic ability is not the result of an association of C with the more favorable luminal A subtype or U with the less favorable luminal B subtype. GR promoter methylation could be assessed in many samples where the original PAM50 test failed (43 out of 208), though it has now been updated to use NanoString technology [39]. The commercial test, Prosigna, is typically used to stratify patients into risk groups where those with the lowest risk are spared aggressive treatment [49]. The C region biomarker could serve as an ancillary marker and being based on DNA methylation, which we have demonstrated to be very robust and resistant to normal contamination, may be applicable to samples that are otherwise unable to be assessed, for example, due to RNA degradation. In contrast, patients with U methylation who did not receive tamoxifen had particularly early relapse and death which was only partially improved with tamoxifen treatment. This may reflect a need for GR function for effective anti-estrogen action [13] or may identify tumors that have already gained estrogen independence [50]. This would be an intrinsic, rather than acquired prop-
erty of the tumor, as it was assessed in the primary tissue. These patients could be treated more aggressively in an attempt to compensate for the ineffectiveness of anti-estrogen therapy.

This MA.12 cohort was comprised of relatively young breast cancer patients (60% less than 45 years old) but the TCGA and KM plotter data all point to these results being applicable to older women as well. The confirm-
ation of this work will require validation in additional cohorts that are more reflective of the overall pre- and post-menopausal breast cancer populations.

Conclusions
Our results suggest that in ER+ breast cancers, the status of the GR gene, as reflected by promoter methylation, may define a previously uncharacterized subset of pa-
tients and that GR methylation status plays an important role in determining the response to treatment and ultim-
ately determines the prognosis of some of these patients.

Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.1186/s13148-019-0750-x.

Acknowledgements
The authors thank the women who participated in the CCTG MA.12 study and the Central Tumour/Tissue Repository of the CCTG (Kingston, ON, Canada), particularly Shakeel Virk for his assistance. Biological materials were also provided by the Ontario Tumour Bank, which is supported by the

Additional file 1: Table S1. Primers for quantitative Methylation-
Specific PCR (qMSP).

Additional file 2: Table S2. Genomic coordinates for all GR promoter methylation primers and probes.

Additional file 3: Table S3. GR methylation in U and C regions for patients by outcome.

Additional file 4: Table S4. Association of GR methylation and clinical characteristics in MA.12 GR methylation study patients.

Additional file 5: Table S5. Association of GR methylation groups (based on methylation of C and U promoter regions) and clinical characteristics in MA.12 GR methylation study patients.

Additional file 6: Figure S1. Comparison of GR methylation values generated by singleplex and multiplex GR bisulfite sequencing assay methods in breast tumor samples. DNA from fresh frozen breast tumors (n = 11) was tested by both the singleplex and the multiplex GR bisulfite sequencing assay and the methylation values for each primer set in the assay were compared using a Pearson correlation. There was a strong positive correlation between the two tests and all correlations were statistically significant with greater or equal to r = 0.97, P < 0.0001. R² values for the relationship between methylation values are shown for each primer set.

1Acknowledgements
The authors thank the women who participated in the CCTG MA.12 study and the Central Tumour/Tissue Repository of the CCTG (Kingston, ON, Canada), particularly Shakeel Virk for his assistance. Biological materials were also provided by the Ontario Tumour Bank, which is supported by the

Additional file 1: Table S1. Primers for quantitative Methylation-
Specific PCR (qMSP).

Additional file 2: Table S2. Genomic coordinates for all GR promoter methylation primers and probes.

Additional file 3: Table S3. GR methylation in U and C regions for patients by outcome.

Additional file 4: Table S4. Association of GR methylation and clinical characteristics in MA.12 GR methylation study patients.

Additional file 5: Table S5. Association of GR methylation groups (based on methylation of C and U promoter regions) and clinical characteristics in MA.12 GR methylation study patients.

Additional file 6: Figure S1. Comparison of GR methylation values generated by singleplex and multiplex GR bisulfite sequencing assay methods in breast tumor samples. DNA from fresh frozen breast tumors (n = 11) was tested by both the singleplex and the multiplex GR bisulfite sequencing assay and the methylation values for each primer set in the assay were compared using a Pearson correlation. There was a strong positive correlation between the two tests and all correlations were statistically significant with greater or equal to r = 0.97, P < 0.0001. R² values for the relationship between methylation values are shown for each primer set.
Ontario Institute for Cancer Research through funding provided by the Government of Ontario. We thank Lee Boudreau at the Queen’s Laboratory for Molecular Pathology for the extraction of MA.12 sample material, Amelia Perri and Leah Egan for qMSP primer design, and Dr. Parvin Mousavi for supervision of Britnia Villavarajan as part of the Masters of Biomedical Informatics program at Queen’s University. Thanks to Dr. Scott Davey for critical reading of the manuscript. Finally, we thank Dr. Torsten Nielsen for providing us with MA.12 PAM50 data.

**Authors’ contributions**

HS carried out the experiments. HS and CM drafted the manuscript. HS, CM, YP, LS, and BV participated in the analysis and interpretation of data. CM and AR conceived of the study. All authors read and approved the final manuscript.

**Funding**

This work was supported by a grant from the Department of Oncology, Cancer Centre of Southeastern Ontario, at Kingston General Hospital, Queen’s University, to AR and CRM. HS was the recipient of a trainee grant from the Terry Fox Foundation Training Program in Transdisciplinary Cancer Research in Partnership with the Canadian Institutes of Health Research (CIHR).

**Availability of data and materials**

The datasets analyzed here are available from the TCGA Research Network (available at: http://cancergenomewiki.cancer.gov/) and Kaplan-Meier plotter (available at: http://kmplot.com/analysis/). All other data generated and/or analyzed during the current study are available from the corresponding author on reasonable request.

**Ethics approval and consent to participate**

This work was performed with the approval of the Health Sciences Research Ethics Board of Queen’s University, Kingston, Ontario, Canada. 6Canadian Cancer Trials Group, Queen’s University, at Kingston General Hospital, Queen’s Cancer Research Institute, Queen’s University, Kingston, Ontario, Canada. 7Department of Public Health Sciences, Queen’s University, Kingston, Ontario, Canada. 8Department of Biomedical and Molecular Sciences, Queen’s University, Kingston, Ontario, Canada. 9Canadian Cancer Trials Group, Queen’s University, Kingston, Ontario, Canada. 10Division of Oncology, Division of Medical Oncology, Queen’s University, Kingston, Ontario, Canada. 11Division of Biomedical and Molecular Sciences, Queen’s University, Kingston, Ontario, Canada.

**Consent for publication**

Not applicable.

**Competing interests**

Dr. Christopher Mueller is a co-holder of a patent on the analysis of glucocorticoid receptor promoter methylation in breast cancer. There is no current financial activity related to this patent. The other authors declare that they have no competing interests.

**Author details**

1Division of Cancer Biology and Genetics, Queen’s Cancer Research Institute, Queen’s University, Kingston, Ontario, Canada. 2Department of Pathology and Molecular Medicine, Queen’s University, Kingston, Ontario, Canada. 3Division of Cancer Care and Epidemiology, Queen’s Cancer Research Institute, Queen’s University, Kingston, Ontario, Canada. 4Department of Mathematics and Statistics, Queen’s University, Kingston, Ontario, Canada. 5Department of Public Health Sciences, Queen’s University, Kingston, Ontario, Canada. 6Canadian Cancer Trials Group, Queen’s University, Kingston, Ontario, Canada. 7Division of Oncology, Division of Medical Oncology, Queen’s University, Kingston, Ontario, Canada. 8Department of Biomedical and Molecular Sciences, Queen’s University, Kingston, Ontario, Canada.

**Received:** 29 July 2019 **Accepted:** 22 September 2019 **Published online:** 01 November 2019

**References**

1. Kos Z, Dabbs DJ. Biomarker assessment and molecular testing for prognostication in breast cancer. Histopathology. 2016;68:70–85.
2. Nicolini A, Ferrari P, Duffy MJ. Prognostic and predictive biomarkers in breast cancer: past, present and future. Semin Cancer Biol. 2018;52:56–73.
3. Early Breast Cancer Trials’ Collaborative Group (EBCTCG). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378:771–84.
4. Early Breast Cancer Trials’ Collaborative Group (EBCTCG). Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trials’ Collaborative Group. Lancet. 1998;351:1451–67.
5. Early Breast Cancer Trials’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687–717.
6. Early Breast Cancer Trials’ Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet. 2015;386:1341–52.
7. Kwa M, Makris A, Esteva FJ. Clinical utility of gene-expression signatures in early stage breast cancer. Nat Rev Clin Oncol. 2017;14:595–610.
8. Markopoulou C, van de Velde C, Zarca D, Ozmen V, Masetti R. Clinical evidence supporting genomic tests in early breast cancer: do all genomic tests provide the same information? Eur J Surg Oncol. 2017;43:909–20.
9. Katzenellenbogen JA, Mayne CG, Katzenellenbogen BS, Greene GL, Chandraratna S. Structural underpinnings of oestrogen receptor mutations in endocrine therapy resistance. Nat Rev Cancer. 2018;18:377.
10. Truong TH, Lange CA. Deciphering steroid receptor crosstalk in hormone-driven cancers. Endocrinology. 2019;159:3897–907.
11. Skora MJ. Family matters: collaboration and conflict among the steroid receptors raises a need for group therapy. Endocrinology. 2016;157:4533–60.
12. Sersbø R, Kumar S, Carroll JS. Signaling pathways and steroid receptors modulating estrogen receptor a function in breast cancer. Genes Dev. 2018;32:141–54.
13. West DC, Pan D, Tonsing-Carter EY, Hernandez KM, Pierce CF, Styke SC, et al. GR and ER coactivation alters the expression of differentiation genes and associates with improved ER+ breast cancer outcome. Mol Cancer Res. 2016;14:707–19.
14. Bolt MI, Stossi F, Newberg JY, Orjalo A, Johansson HE, Mancini MA. Coactivators enable glucocorticoid receptor recruitment to fine-tune estrogen receptor transcriptional responses. Nuclear Receptors. 2013;41:4036–48.
15. Karmakar S, Jin Y, Nagaich AK. Interaction of glucocorticoid receptor (GR) with estrogen receptor (ER) a and activator protein 1 (AP1) in dexamethasone-mediated interference of ERα activity. J Biol Chem. 2013;288:24020–34.
16. Miranda TB, Voss TC, Sung M-H, Baek S, John S, Hawkins M, et al. Reprogramming the chromatin landscape: Interplay of the estrogen and glucocorticoid receptors at the genomic level. Cancer Res. 2013;73:3510–9.
17. Yang F, Ma Q, Liu Z, Li W, Tan Y, Jin C, et al. Glucocorticoid receptor: MegaTrans switching mediates the repression of an ERα-regulated transcriptional program. Mol Cell. 2017;66:321–31 e6.
18. Pan D, Kocherginsky M, Conen SD. Activation of the glucocorticoid receptor is associated with poor prognosis in estrogen receptor-negative breast cancer. Cancer Res. 2011;71:6360–70.
19. Abduljabbar R, Negm OH, Lai C-F, Jerjees DA, Al-Kaabi M, Hamed MR, et al. Clinical and biological significance of glucocorticoid receptor (GR) expression in breast cancer. Breast Cancer Res Treat. 2015;150:335–46.
20. Buxant F, Engdahl-Aloge C, Noell J-C. Estrogen receptor, progesterone receptor, and glucocorticoid receptor expression in normal breast tissue, breast in situ carcinoma, and invasive breast cancer. Appl Immunohistochem Mol Morphol. 2010;18:254–7.
21. Conde I, Paniagua R, Fraile B, Lucio J, Arenas MI. Glucocorticoid receptor changes its cellular location with breast cancer development. Histol Histopathol. 2008;23:77–85.
22. Belova L, Delgado B, Kocherginsky M, Melhem A, Olopade OI, Conen SD. Glucocorticoid receptor expression in breast cancer associates with older patient age. Breast Cancer Res Treat. 2009;116:441–7.
23. Lien H-C, Lu Y-S, Cheng A-L, Chang W-C, Jeng Y-M, Kuo Y-H, et al. Differential expression of glucocorticoid receptor in human breast tissues and related neoplasms. J Pathol. 2006;209:317–27.
24. Nesse RT, Perri AM, Mueller CR. Frequent promoter hypermethylation and expression reduction of the glucocorticoid receptor gene in breast tumors. Epigenetics. 2014;9:851–9.
25. Bramwell VHC, Pritchard KL, Tu D, Tonkin K, Yachshajani H, Vandenberg TA, et al. A randomized placebo-controlled study of tamoxifen after adjuvant chemotherapy in premenopausal women with early breast cancer (National Cancer Institute of Canada—Clinical Trials Group Trial, MA.12). Ann Oncol. 2010;21:283–90.
26. Li LC, Dahlya R. MethPrimer: designing primers for methylation PCRs. Bioinformatics. 2002;18:1427–31.
27. McCormick JA, Lyons V, Jacobson MD, Noble J, Diorio J, Nyrenda M, et al. S'-heterogeneity of glucocorticoid receptor messenger RNA is tissue specific: differential regulation of variant transcripts by early-life events. Mol Endocrinol. 2000;14:506–17.
28. Afgan E, Barker D, van den Beek M, Blankenberg D, Bouvier D, Cech M, et al. The galaxy platform for accessible, reproducible and collaborative biomedical analyses: 2016 update. Nucleic Acids Res. 2016;44:W5–10.
29. Becker D, Lutsik P, Ebert P, Bock C, Lengauer T, Walter J. BQ Analyzer HiMod: an interactive software tool for high-throughput locus-specific analysis of 5-methylcytosine and its oxidized derivatives. Nucleic Acids Res. 2014;42:W591–7.
30. Győrffy B, Lanczyk A, Eldund AC, Denkert C, Budczies J, Li Q, et al. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat. 2010;123:725–31.
31. Turner JD, Alt SP, Liao G, Vercoucke S, Batteletto N, et al. Transcriptional control of the glucocorticoid receptor: CpG islands, epigenetics and more. Biochem Pharmacol. 2010;80:1860–8.
32. Cao-Lei L, Leija SC, Kumsta R, Wüst S, Meyer J, Turner JD, et al. Transcriptional control of the human glucocorticoid receptor: identification and analysis of alternative promoter regions. Hum Genet. 2011;129:533–43.
33. Guyard A, Boyez A, Pujalet A, Robe C, Tran Van Nhieu J, Alley Y, et al. DNA degradation during storage in formalin-fixed and paraffin-embedded tissue blocks. Virchows Arch. 2012;471:491–500.
34. Kint S, De Spiegelaere W, De Kesel J, Vandekerckhove L, Van Criekinge W. Evaluation of bisulfite kits for DNA methylation profiling in terms of DNA fragmentation and DNA recovery using digital PCR. PLoS One. 2018;13:e0199091.
35. Chia SK, Bramwell VH, Tu D, Shepherd LE, Jiang S, Vickery T, et al. A 50-gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifen. Clin Cancer Res. 2012;18:4466–72.
36. Stefansson OA, Moran S, Gomez A, Sayols S, Arribas-Jorba C, Sandoval J, et al. A DNA methylation-based definition of biologically distinct breast cancer subtypes. Mol Oncol. 2015;9:555–68.
37. Bediaga NG, Beristain E, Calvo B, Viguiri MA, Gutierrez-Corres B, Rezola R, et al. Luminal B breast cancer subtype displays a dicotomic epigenetic pattern. Springerplus. 2016;5:623.
38. Liu J, Lichtenberg T, Hoadley KA, Poisson LM, Lazar AJ, Cherniack AD, et al. An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics. Cell. 2018;173:400–16 e11.
39. Walden B, Storhoff J, Nielsen T, Dowidar N, Schaper C, Ferree S, et al. Development and verification of the PAM50-based Prosigna breast cancer gene signature assay. BMC Med Genet. 2015;8:54.
40. Györffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q, et al. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat. 2010;123:725–31.
41. Terry MB, McDonald JA, Wu HC, Eng S, Santella RM. Epigenetic biomarkers of breast cancer risk: across the breast cancer prevention continuum. Adv Exp Med Biol. 2016;882:33–68.
42. Milkozs CA, Brickley DR, Sharkey MS, Moran TW, Conzen SD. Glucocorticoid receptor-mediated protection from apoptosis is associated with induction of the serine/threonine survival kinase gene, sgk-1. J Biol Chem. 2001;276:16649–54.
43. Obradović M, Mansell B, Manevski N, Couto JP, Sethi A, Cairns RJ, et al. Glucocorticoids promote breast cancer metastasis. Nature. 2019;567:540.
44. Perou CM. Molecular stratification of triple-negative breast cancers. Oncologist. 2010;15:39–48.
45. Tonsing-Carter E, Hernandez KM, Kim CR, Hanks ES, Oh A, Bowie KR, et al. Glucocorticoid receptor modulation decreases ER-positive breast cancer cell proliferation and suppresses wild-type and mutant ER chromatin association. Breast Cancer Res. 2019;21:82.
46. Ritter HD, Mueller CR. Expression microarray identifies the unliganded glucocorticoid receptor as a regulator of gene expression in mammary epithelial cells. BMC Cancer. 2014;14:275.
47. Ritter HD, Antonova L, Mueller CR. The unliganded glucocorticoid receptor positively regulates the tumor suppressor gene BCA1 through GABP beta. Mol Cancer Res. 2012;10:558–69.
48. Antonova L, Aronson K, Mueller CR. Stress and breast cancer: from epidemiology to molecular biology. Breast Cancer Res. 2011;13:208.
49. Ohnstad HO, Borgen E, Falk RS, Lien TG, Aaserud M, Svein MAT, et al. Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up. Breast Cancer Res. 2017;19:120.
50. Musgrove EA, Sutherland RL. Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer. 2009;9:531–43.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.